The long awaited guidance on the use of Nintedanib to treat IPF has been published by NICE.
Nintedanib for treating idiopathic pulmonary fibrosis
NICE technology appraisal guidance [TA379] Published date: January 2016
To download the full guidance go to http://www.nice.org.uk/guidance/ta379
The National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires clinical commissioning groups, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this appraisal within 3 months of its date of publication. While NHS in Wales must usually provide funding and resources for it within 3 months of the guidance being published.
This is good news for patients with IPF who should soon have more than one treatment option available to them.